As we know, there are three major categories of medicines according to their sources, including natural medicines, chemically synthesized drugs, and biological therapeutics.
Among them, biological therapeutics (aka. biologics) are drugs developed and manufactured through biotechnology, such genetic engineering, cell engineering, and protein engineering. Two major categories of biopharmaceuticals have been small molecule- and protein/antibody-based biologics.
Recently, fueled by the global use of mRNA-based COVID-19 vaccines and nucleic acid-based testing for the SARS-CoV-2 virus, the new wave of nucleic acid-based medicine development and production has started taking off (pdf). Furthermore, the increasing number of nucleic acid drugs approved by the U.S. Food and Drug Administration (FDA) demonstrates the potential to treat diseases by targeting the genes responsible for them.
Nucleic acid therapeutics are based on nucleic acids or closely related chemical compounds, and they are completely different from small molecule drugs and antibody drugs.
Instead of targeting protein causes of diseases, they target disease on a genetic level.
Nucleic acid drugs are currently classified into four categories, including medicines based on antisense oligonucleotides (ASOs), small interfering nucleic acids (siRNAs), microRNAs (miRNAs), and nucleic acid aptamers (aptamers).
siRNA and miRNA drugs are called RNA interference (RNAi) medicines.
ASO and siRNA drugs have been approved, and both mainly act on cytoplasmic messenger RNAs (mRNA) to achieve regulation of protein expression through base complementary recognition and inhibition of target mRNAs for the purpose of treating unmet medical needs.
According to the central dogma of molecular biology, DNA is transcribed into RNA, which is then translated into proteins. In some specific cases, RNA can be reverse transcribed into DNA. So, we can see that RNA is critical, because it determines what proteins can be expressed.
Therefore, scientists are trying to see if the process of gene expression can be regulated. That is, instead of interfering at the DNA level, scientists try to regulate the RNA, which is produced in the nucleus and then moves to the cytoplasm. The production of proteins is also carried out in the cytoplasm. If drugs can be absorbed by cells, enter the cytoplasm, and influence the process of translating RNA into proteins, then these drugs can also treat related diseases.
Nucleic acid drugs are designed around this rationale to interfere with the synthesis of disease-causing proteins to treat certain diseases.
ASO is a single-stranded oligonucleotide molecule that enters the cell and binds to the target mRNA through sequence complementation. Then, under the action of ribonuclease H1 (RNase H1), this piece of RNA will be degraded and the expression of the disease-causing proteins will be inhibited consequently.
Both siRNA and miRNAtreat diseases through RNA interference, but their molecules have different properties.
siRNAs are encoded by transposons, viruses, and heterochromatin; whereas miRNAs are encoded by their own genes.
miRNAs can regulate different genes, while siRNAs are called the silencing RNAs, as they mediate the silencing of the same or similar genes from which they originate.
miRNAs are single RNAs and have an imperfect stem-loop secondary structure.
siRNA is a class of double-stranded short RNA molecules that bind to specific Dicer enzymes to degrade one strand. Then the other strand will bind to other enzymes including Argonaute Proteins (AGO) to assemble into a RNA-induced silencing complex (RISC).
In the RISC, the single strand RNA will bind to a target mRNA through the principle of base complementary pairing. Subsequently, the target mRNA will be degraded in the RISC complex, thus blocking the expression of the target protein for the purpose of treating a disease.
This mechanism of inhibiting protein expression via siRNA is called RNA interference. The scientists that had discovered RNA interferencegene silencing by double-stranded RNAwere awarded the Nobel Prize in Physiology or Medicine in 2006.
In terms of therapeutic areas, ASO drugs are mostly developed to cure cancers, infections, as well as neurological, musculoskeletal, ocular, and endocrine diseases.
For instance, fomivirsen, manufactured by Ionis/Novartis, was the first FDA-approved ASO drug, and it is currently used as a second-line treatment for cytomegalovirus (CMV) retinitis. Second-line treatment is used after the first-line (initial) treatment for a disease or condition fails or has intolerable side effects.
Several ASO drugs are also used for treatment of certain rare diseases, including Kynamro (phosphorothioate oligonucleotide drug for the treatment of the rare disease of Homozygous familial hypercholesterolaemia [HoFH]), Exondys 51 (for the treatment of a rare disease called Duchenne muscular dystrophy [DMD]), and Spinraza (for the treatment of spinal muscular atrophy [SMA], a rare inherited disease).
Prior to the development of these medicines, these rare diseases didnt have any effective drugs for treatment.
siRNA drugs therapeutic areas include cancers, infections, as well as neurological, ocular, endocrine, gastrointestinal, cardiovascular, dermatologic, and respiratory diseases.
For instance, patisiran, produced by Alnylam/Genzyme, is the first siRNA drug, and it is used for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis (haTTR). And the worlds second siRNA drug, Givlaari, produced also by Alnylam, was designed and developed for the treatment of acute hepatic porphyria (AHP), which is a family of ultra-rare disease in adults.
The main manufacturer of ASO drugs is the California-based Ionis Pharmaceuticals. The other major ones include ProQR, Sarepta, WAVELife Sciences, Biogen, and Exicure.
The largest manufacturer of siRNA drugs is Alnylam, a Massachusetts-based biopharmaceutical company specializing in the development and manufacturing of RNA interference therapeutics. The other major producers of these medicines include Dicerna, Quark, and Arrowhead.
In terms of the current status of ASO drug development, most of the therapeutics are in the preclinical stage, with their therapeutic areas mainly focused on oncological, neurological, and muscular diseases. The second largest group of ASO drugs are still in their discovery stage, during which medicines are being designed and undergoing preliminary experiments.
The situation with siRNA drugs (pdf) is similar to that of ASO medicines, with the largest group of medicines being in the preclinical stage, and the second largest group in the discovery stage. Currently, five siRNA drugs have been approved, including patisiran, givosiran, inclisiran, lumasiran, and vutrisiran. In addition, around a dozen other drugs are in late stages of phase III clinical trials.
Therefore, in both categories, only a small percentage of drugs have already been launched.
Nucleic acid drugs are considered novel therapeutic modalities, as they have great potential to treat diseases that cannot be treated effectively in the past, such as certain cancers, and some rare diseases for which no small molecule or protein/antibody-based biologics were developed.
In comparison with small molecule drugs and antibody-based biologics, nucleic acid-based therapeutics have high specificity towards RNAs.
Furthermore, they have simple designs and rapid and cost-effective development cycles (which would later translate into lower costs for patients), as their preclinical research and development starts with gene sequence determination and reasonable designs for disease genes, the genes can be targeted and silenced, thus avoiding unnecessary development and greatly saving research and development time.
They can also quickly alter the sequence of the mRNA construct for personalized treatments or to adapt to an evolving pathogen.In addition, they have abundant targets, so they can potentially make a breakthrough for some special targets that were previously undruggable, to treat certain genetic diseases. And the RNA interference technology has already matured in terms of target selection and small RNA segment synthesis.
However, getting the small RNA segment generated is only the initial step of drug development. In order for nucleic acid drugs to be applied clinically, the next important issue is delivering the nucleic acids to target tissues and cells. Since nucleic acids are highly hydrophilic and polyvalent anionic, it is not easy for cell uptake.
The selection of different delivery mechanisms of genes or RNA agents can impact the increase or decrease the expression of proteins in a cell.
The commonly used (pdf) nucleic acid drug delivery systems include drug conjugates (such as antibody-siRNA conjugates and cholesterol-siRNA conjugates), lipid-based nanocarriers (such as stealth liposomes and lipid nanoparticles), polymeric nanocarriers (such as nanoparticles base on degradable or non-degradable polymers and dendrimers), inorganic nanocarriers (such as silica nanoparticles and metal nanoparticles), carbon-based nanoparticles, quantum dots, and natural extracellular vesicles (ECVs).
Just like almost all drugs, nucleic acid therapeutics also have side effects and risks, some of which stem from their delivery methods.
The common adverse drug reactions (ADRs) of FDA-approved ASO drugs include injection site reactions (e.g. swelling), headache, pyrexia, fever, respiratory infection, cough, vomiting, and nausea (pdf). Individual ASO drugs have their own respective side effects. For instance, fomivirsen can potentially increase intraocular pressure and ocular infection. Pegaptanib can cause conjunctival hemorrhage, corneal edema, visual disturbance, and vitreous floaters. The ADRs of mipomersen (Kynamro) resemble flu symptoms. Nusinersen can cause fatigue and thrombocytopenia. And inotersen can also cause contact dermatitis.
Users of ASO drugs should also be aware of hepatotoxicity, kidney toxicity, and hypersensitive reactions (pdf).
Inotersen (Tegsedi) even carries black box warnings, which are required by the FDA for medications that carry serious safety risks, against its severe side effects, including thrombocytopenia, glomerulonephritis, and renal toxicity. Furthermore, users of inotersen are warned against possible reduced serum vitamin A, stroke, and cervicocephalic arterial dissection.
Side effects of siRNA drugs are similar to those of ASO drugs, including nausea, injection site reactions, heart block, vertigo, blurred vision, liver failure, kidney dysfunction, muscle spasms, fatigue, abdominal pain, and the potentially life-threatening anaphylaxis.
Specifically, during clinical trials of givosiran, one siRNA drug, 15 percent of subjects reported alanine aminotransferase (ALT) elevations three times above the normal range, and 15 percent reported elevated serum creatinine levels and reductions in estimated Glomerular Filtration Rate (eGFR), both signs of poor kidney function. Therefore, liver and kidney toxicity was reported during these clinical trials.
The use of siRNA drugs by pregnant mothers may entail risks for their unborn children. So far, although data on using givosiran, patisiran, and lumasiran have not been reported, certain ADRs of these drugs can serve as warning signs for use during pregnancy. For instance, patients using patisiran (Onpattro) will experience a reduction in their vitamin A levels. Vitamin A is essential for the unborn babys developing organs such as eyes and bones, as well asits circulatory, respiratory, and central nervous systems. Also, givosiran is shown to cause unfavorable developmental effects on animals. Furthermore, inclisiran therapy is not recommended for pregnant mothers, as it may harm the fetus.
In order for nucleic acid drugs to be effective, their design and development need to overcome a number of challenges, such as nuclease degradation, short half-life, immune recognition in circulation, accumulation in target tissues, transmembrane transport, and endosomal escape. Although nuclease stability and avoidance of immune recognition can be greatly reduced by combining chemical modifications, other problems remain to be solved.
Since carrier systems can greatly solve the problems that cannot be solved by chemical modifications and enhance the effectiveness and safety of nucleic acid drug therapeutics, these carrier systems are considered by many as the most important for development and overcoming the aforementioned challenges.
Currently, siRNA drug development faces several challenges (pdf), such as efficacy in siRNA delivery, safety, biocompatibility/biodegradability, and issues of their production, standardization, and approval as multi-component systems.
For example, in the case of lipid nanoparticles (LNPs; one type of lipid-based nanocarriers), only 1 to 2 percent of the internalized siRNAs are released into the cytoplasm. Therefore, research should be focusing on making nanoparticles capable of increasing the release of siRNAs.
However, it should also be noted that the safety, biodistribution, biokinetics, clearance or accumulation of LNPs in different tissues and organs are not well characterized for different types of LNPs. Therefore, the side effects or adverse reactions triggered by this delivery system should also be carefully studied.
The unprecedented global usage of mRNA vaccines under the context of pandemic has given a very unusual momentum to drive more RNA-based therapeutic development. However, clear and calm minds are still needed to see the challenges and explore the safety and risks issues comprehensively and longitudinally for any newly designed RNA-based therapeutic drugs.
Read the original here:
COVID mRNA Jabs and Testing Kicked Off This Industry of Drug Development: Here's What You Need to Know - The Epoch Times
- Principles of Genetic Engineering - PMC - National Center for ... - March 28th, 2024
- Historic Overview of Genetic Engineering Technologies for Human Gene ... - March 28th, 2024
- 20.3: Genetic Engineering - Biology LibreTexts - December 10th, 2023
- Genetically modified organism - Wikipedia - November 16th, 2023
- Genetic engineering - DNA Modification, Cloning, Gene Splicing - November 16th, 2023
- 18 Human Genetic Engineering - Clemson University - April 7th, 2023
- Pros and Cons of Genetic Engineering - Benefits and Risks - April 7th, 2023
- Genetic Engineering - Meaning, Applications, Advantages and Challenges ... - March 12th, 2023
- Genetic Engineering Principles of Biology - December 27th, 2022
- Engineering the Perfect Baby | MIT Technology Review - December 27th, 2022
- What is CRISPR? | Live Science - November 24th, 2022
- To modify or not to modify? Genetic Modification and Gene Editing - A divergence by the UK - Lexology - October 13th, 2022
- DNA and the impossibility of research in isolation - Morning Star Online - October 13th, 2022
- Genome editing technologies: final conclusions of the re-examination of Article 13 of the Oviedo Convention - Council of Europe - October 13th, 2022
- Approval, Commercialization Highlighted at Cell & Gene Meeting on the Mesa - Genetic Engineering & Biotechnology News - October 13th, 2022
- Dissatisfaction and New Articulations - Discovery Institute - October 13th, 2022
- In 'The Cultivar Series,' Uli Westphal Gets to the Root of Crop Diversity and Agricultural Modification - Colossal - October 13th, 2022
- Genomic Research Aids in the Effort to Understand How Best to Treat Deadly Infections Caused by a Fungus - UMass News and Media Relations - October 13th, 2022
- Synthetic Biology Market is Expected to Report a CAGR of ~21% from 2021 to 2029: Industry Size, Growth & Forecast at Douglas Insights - Yahoo... - October 13th, 2022
- Farmers, consumers will embrace GMOs if they understand them - The Standard - October 13th, 2022
- Emily Whitten: The limits of science and human intelligence - WORLD News Group - October 13th, 2022
- Behind this Nobel prize is a very human story: theres a bit of Neanderthal in all of us - The Guardian - October 13th, 2022
- Earth materials in technology The National - The National - October 13th, 2022
- Gene therapy brings hope to people with sickle cell, HIV - Monitor - October 13th, 2022
- Eligo Bioscience Receives FDA Orphan Drug Designation (ODD) and Rare Pediatric Disease (RPD) Designation for EB003 for the Prevention of Hemolytic... - October 13th, 2022
- Skin Grafting, Cryopreservation, and Diseases: A Review Article - Cureus - October 13th, 2022
- Cultured meat could help solve the climate crisis. Heres what it will take to move it from the lab to the dinner table - Fortune - October 13th, 2022
- Ignore scary messages: We've never had it so good & that's not manure - West Side Index & Gustine Press-Standard - October 13th, 2022
- Global Phosphoramidite Market Report 2022: Increasing Synthetic Nucleotide Applications in Therapeutics Drives Growth - ResearchAndMarkets.com -... - October 13th, 2022
- Enzymes Market worth $16.9 billion by 2027 - Exclusive Report by MarketsandMarkets - Yahoo Finance - October 4th, 2022
- Experts Sound Alarm Over 'Growing Threat' of Genetically Engineered Trees - Common Dreams - October 4th, 2022
- Scientists are manipulating the DNA of mosquitoes to fight the spread of malaria - Euronews - October 4th, 2022
- Smile Coffee Werks upgraded its coffee beans to Fair Trade and USDA Organic - Vending Market Watch - October 4th, 2022
- 22nd Century Group (Nasdaq: XXII) Expands VLN Distributor Network with the Addition of Specialty Distrib - Benzinga - October 4th, 2022
- Researchers are seeking to develop spuds that resist harmful nematodes - FreshPlaza.com - October 4th, 2022
- Synthetic biology has the power to cure and kill. How will we use it? - Big Think - September 25th, 2022
- SPECIAL REPORT: Bioengineered food labeling: 'They kind of shot in the middle and missed every constituency' - FoodNavigator-USA.com - September 25th, 2022
- Yeast-Fermented Chemo: Now We Can Brew Anything - Medscape - September 25th, 2022
- September 23, 2022: The Integrity of Marius Mason WFHB - WFHB News - September 25th, 2022
- 2 Risky Cathie Wood Growth Stocks to Buy and Hold for 5 Years - The Motley Fool - September 25th, 2022
- Bananas threatened by devastating fungus given temporary resistance - New Scientist - September 25th, 2022
- 'What Hath God Wrought' - Today, Luddites Are Concerned About Weedkillers Like They Once Were The Telegraph - Science 2.0 - September 25th, 2022
- Children should be educated about oral health and hygiene - Star of Mysore - September 25th, 2022
- Id rather eat an actual burger: why plant-based meats sizzle fizzled in the US - The Guardian - September 25th, 2022
- Health Tech startups are booming. These 11 VC investors are behind some of the hottest deals - Fortune - September 25th, 2022
- Last Chance This Fall to Tell the NOSB To Uphold Organic Integrity - Beyond Pesticides - September 25th, 2022
- Cambodian PM begins official visit to Cuba - Khmer Times - September 25th, 2022
- Researchers develop method to prevent spread of melanoma to brain - Xinhua - September 25th, 2022
- I'm allergic to the cat, what can I do? - Surinenglish.com - September 25th, 2022
- Researchers Propose a New Way of Regulating Engineered Crops - Modern Farmer - September 16th, 2022
- Purple Tomato is first genetically engineered plant to be deregulated through USDA's new regulatory status review process - Lexology - September 16th, 2022
- Genetically Modified Feed Market to Hit $135 billion by 2030, says Global Market Insights Inc. - Yahoo Finance - September 16th, 2022
- Africa, GMOs and Western Interests - DW (English) - September 16th, 2022
- The science behind the oil supply breakdown in 'Last Light' - Syfy - September 16th, 2022
- Inside the controversial plan to bring extinct animals back from the dead - The Independent - September 16th, 2022
- Star Trek Actor Says Their Trek Hero Is Just Like Their Marvel Character - Giant Freakin Robot - September 16th, 2022
- Scientists closer to making blood stem cells in the lab - Cosmos - September 16th, 2022
- Oncolytic Cancer Therapies Market is expected to grow at a CAGR of 33% by 2032 | DelveInsight - Digital Journal - September 16th, 2022
- Don't call it waste - it can be turned into hydrogen if you handle it right - Innovation Origins - September 16th, 2022
- Can gene editing ease the cost of living crisis? - The Grocer - September 8th, 2022
- Gene editing could revive the American chestnut tree and help fight climate change but familiar anti-biotechonology activist critics will have none... - September 8th, 2022
- Colossal to de-extinct the Tasmanian tiger. Is it a safe thing to do? - Cape Cod Times - September 8th, 2022
- The Future of Nanotech, the World's Tiniest Industry - Entrepreneur - September 8th, 2022
- Viewpoint: The 'natural food' sham 'Effective communication on the ethics of science may be hindered by appeals to naturalness' - Genetic Literacy... - September 8th, 2022
- Toray says it has developed the worlds first 100% bio-based adipic acid - Biofuels Digest - September 8th, 2022
- Chinese scientists claim to have engineered the world's first mouse with fully reprogrammed genes - Interesting Engineering - August 30th, 2022
- Century Therapeutics Receives Study May Proceed Notification from FDA for CNTY-101, the First Allogeneic Cell Therapy Product Candidate Engineered to... - August 30th, 2022
- Living Carbon: The startup setting down roots from 9 to 5 | Greenbiz - GreenBiz - August 30th, 2022
- Novavax Nuvaxovid COVID-19 Vaccine Granted Expanded Conditional Marketing Authorization in the United Kingdom for Use in Adolescents Aged 12 Through... - August 30th, 2022
- Genetics in fiction - Wikipedia - August 14th, 2022
- Weeds superpower could help feed the planet - Freethink - August 14th, 2022
- POSEIDA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) - Marketscreener.com - August 14th, 2022
- Novartis Confirms Deaths of Two Patients Treated with Gene Therapy Zolgensma - Genetic Engineering & Biotechnology News - August 14th, 2022
- LETTER TO THE EDITOR: Lessons from 1984 | Letters To Editor | carolinacoastonline.com - Carolinacoastonline - August 14th, 2022
- How Arkeon Biotechnologies is turning CO2 into food: 'Excuse my language, but this is next-level cool' - FoodNavigator.com - August 14th, 2022
- Synlogic Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks - PR Newswire - August 14th, 2022
- THE SAD STORY OF THE REJECTION OF SCIENCE - Sp Supplements - DAWN.COM - DAWN.com - August 14th, 2022
- Global Genome Editing Technologies market is projected to grow at a CAGR of 15.96% by 2032: Visiongain Reports Ltd - Yahoo Finance - August 5th, 2022
- I Got Critiqued by YouTuber Gutsick Gibbon - Discovery Institute - August 5th, 2022
- CRISPR Technology in the Agricultural Industry: Patent and Regulatory Updates - JD Supra - August 5th, 2022